Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Even if resM works as intended, the effects are gradual
the difference is packaging, oversight, and price
The plotter shows that at four weeks, you are at approximately 94% of steady state
Dosing fundamentals Administration: Once weekly subcutaneous injection Same day each week (consistency matters) Preferably at the same time of day Half-life: Approximately 6 days, supporting weekly dosing Dose escalation: Every 4 weeks, unless: Side effects require holding current dose Individual tolerance suggests faster/slower progression Healthcare provider recommends adjustment Clinical trial doses tested The Phase 2 obesity trial tested multiple dosing arms: Key insight: 8 mg produces nearly the same results as 12 mg with fewer side effectsmaking it a potential "sweet spot" for many users
Long-acting GLP-1 receptor agonists provide sustained receptor activation and clinically meaningful improvements in glycaemic control and weight in eligible patients, as recognised in NICE guidance (NG28) for type 2 diabetes management
